Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

CG Therapeutics, U of W form monoclonal antibody program
April 2008
SHARING OPTIONS:

SEATTLEŚCG Therapeutics, a biotechnology company developing new cancer immunotherapies, announced that it has undertaken a joint monoclonal antibody development program with the University of Washington. CG Therapeutics is commercializing CG201, a proprietary vaccine that produces antibodies that neutralize hCG, a powerful hormone produced by tumor cells to speed their growth. The new, joint program will develop human monoclonal antibodies against hCG that can be used with the CG201 vaccine to provide a comprehensive cancer treatment. The program will be headed by University of Washington researchers Drs. Karl Eric and Ingegerd Hellstrom, who are renowned for their pioneering work in the application of monoclonal antibodies in the cancer field.
 
"We look forward to collaborating with the Hellstroms, who were among the first researchers to demonstrate immune responses to tumors and produce monoclonal antibodies to human cancers," says Tom Hopp, vice president of research for CG Therapeutics. "hCG is a promising oncology target and this research collaboration is poised to significantly enhance our efforts toward the development of effective hCG therapeutics."

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.